{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:52:31Z","timestamp":1789872751903,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T00:00:00Z","timestamp":1448236800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s11096-015-0219-8","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T07:50:31Z","timestamp":1448265031000},"page":"144-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour"],"prefix":"10.1007","volume":"38","author":[{"given":"Stefanie Amarens","family":"de Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop Daniel","family":"Lefrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Japke Frida","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrikus Hessel","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douwe Johannes","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas","family":"Hoogenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,23]]},"reference":[{"key":"219_CR1","first-page":"523","volume":"72","author":"EFS Velsen Van","year":"2014","unstructured":"Van Velsen EFS, Lamers J, Blok V, Van Leendert RJM, Kiewiet-Kemper RM. A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice. Neth J Med. 2014;72:523\u20137.","journal-title":"Neth J Med"},{"key":"219_CR2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4158\/EP.13.5.444","volume":"13","author":"P Viswanathan","year":"2007","unstructured":"Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13:444\u201350.","journal-title":"Endocr Pract"},{"key":"219_CR3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/qjmed\/hcq112","volume":"103","author":"UA Nayak","year":"2010","unstructured":"Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM. 2010;103:687\u201394.","journal-title":"QJM"},{"key":"219_CR4","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsboll","year":"2012","unstructured":"Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.","journal-title":"BMJ"},{"key":"219_CR5","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696\u2013705.","journal-title":"Lancet"},{"key":"219_CR6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1185\/03007995.2013.852078","volume":"30","author":"R Goldenberg","year":"2014","unstructured":"Goldenberg R. Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Curr Med Res Opin. 2014;30:431\u201345.","journal-title":"Curr Med Res Opin"},{"key":"219_CR7","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","volume":"384","author":"C Eng","year":"2014","unstructured":"Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228\u201334.","journal-title":"Lancet"},{"key":"219_CR8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2337\/dc11-1434","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR, et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care. 2012;35:955\u20138.","journal-title":"Diabetes Care"},{"key":"219_CR9","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824\u201330.","journal-title":"Lancet"},{"key":"219_CR10","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","volume":"63","author":"L Bloemendaal Van","year":"2014","unstructured":"Van Bloemendaal L, IJzerman RG, Ten Kulve JS, Barkhof F, Konrad RJ, Drent ML, Veltman DJ, Diamant M. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63:4186\u201396.","journal-title":"Diabetes"},{"key":"219_CR11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI0215595","volume":"110","author":"H Yamamoto","year":"2002","unstructured":"Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43\u201352.","journal-title":"J Clin Invest"},{"key":"219_CR12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.22.7.1137","volume":"22","author":"MB Toft-Nielsen","year":"1999","unstructured":"Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999;22:1137\u201343.","journal-title":"Diabetes Care"},{"key":"219_CR13","doi-asserted-by":"crossref","unstructured":"Robert SA, Ghani RA, Zainuddin S, Shah SA, Mohamud WNW, Kamaruddin NA. The influence of a GLP-1 analogue, liraglutide on binge eating behavior among obese healthy participants. In: Data presented at: Annual Scientific Meeting of the Australian and New Zealand Obesity Society (ANZOS), Melbourne, Australia; Oct 17\u201319 2013.","DOI":"10.1016\/j.orcp.2013.12.576"},{"key":"219_CR14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.physbeh.2008.04.014","volume":"94","author":"CP Herman","year":"2008","unstructured":"Herman CP, Polivy J. External cues in the control of food intake in humans: the sensory-normative distinction. Physiol Behav. 2008;94:722\u20138.","journal-title":"Physiol Behav"},{"key":"219_CR15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jpsychires.2010.03.012","volume":"44","author":"T Strien Van","year":"2010","unstructured":"Van Strien T, van der Zwaluw CS, Engels RC. Emotional eating in adolescents: a gene (SLC6A4\/5-HTT)\u2014depressive feelings interaction analysis. J Psychiatr Res. 2010;44:1035\u201342.","journal-title":"J Psychiatr Res"},{"key":"219_CR16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1037\/0021-843X.84.6.666","volume":"84","author":"CP Herman","year":"1975","unstructured":"Herman CP, Polivy J. Anxiety, restraint, and eating behavior. J Abnorm Psychol. 1975;84:66\u201372.","journal-title":"J Abnorm Psychol"},{"key":"219_CR17","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/oby.2009.116","volume":"17","author":"JP Chaput","year":"2009","unstructured":"Chaput JP, Leblanc C, Perusse L, Despres JP, Bouchard C, Tremblay A. Risk factors for adult overweight and obesity in the Quebec Family Study: Have we been barking up the wrong tree? Obesity (Silver Spring). 2009;17:1964\u201370.","journal-title":"Obesity (Silver Spring)"},{"key":"219_CR18","unstructured":"Van Strien T, Frijters J, Bergers G, Defares P. Nederlandse Vragenlijst voor eetgedrag (NVE). Handleiding [Dutch Eating Behavior Questionnaire Manual]. Lisse; 1986."},{"key":"219_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39\u201347.","journal-title":"Lancet"},{"key":"219_CR20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1475-2840-11-107","volume":"11","author":"Y Fujishima","year":"2012","unstructured":"Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012;11:107.","journal-title":"Cardiovasc Diabetol"},{"key":"219_CR21","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2337\/dc12-1925","volume":"36","author":"H Schlogl","year":"2013","unstructured":"Schlogl H, Kabisch S, Horstmann A, Lohmann G, Muller K, Lepsien J, et al. Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care. 2013;36:1933\u201340.","journal-title":"Diabetes Care"},{"key":"219_CR22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.appet.2014.01.012","volume":"76","author":"RM Banos","year":"2014","unstructured":"Banos RM, Cebolla A, Moragrega I, Van Strien T, Fernandez-Aranda F, Aguera Z, et al. Relationship between eating styles and temperament in an Anorexia Nervosa, Healthy Control, and Morbid Obesity female sample. Appetite. 2014;76:76\u201383.","journal-title":"Appetite"},{"key":"219_CR23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/eat.22264","volume":"48","author":"AM Dossat","year":"2015","unstructured":"Dossat AM, Bodell LP, Williams DL, Eckel LA, Keel PK. Preliminary examination of glucagon-like peptide-1 levels in women with purging disorder and bulimia nervosa. Int J Eat Disord. 2015;48:199\u2013205.","journal-title":"Int J Eat Disord"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0219-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-015-0219-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0219-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0219-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T16:19:10Z","timestamp":1567354750000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-015-0219-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1007\/s11096-015-0219-8","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,23]]}}}